- Home
- KRG vs BLTE Comparison
KRG vs BLTE Comparison
Compare KRG & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRG | BLTE |
|---|---|---|
| Founded | 1971 | 2018 |
| Country | United States | United States |
| Employees | N/A | 41 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.0B |
| IPO Year | 2004 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KRG | BLTE |
|---|---|---|
| Price | $29.24 | $147.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $26.00 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 2.0M | 237.7K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.45% | N/A |
| EPS Growth | ★ 6750.00 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $844,365,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.96 | $492.11 |
| P/E Ratio | $483.50 | ★ N/A |
| Revenue Growth | ★ 0.30 | N/A |
| 52 Week Low | $20.86 | $56.68 |
| 52 Week High | $29.40 | $200.00 |
Technical Indicators
Market Signals| Indicator | KRG | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 68.03 | 51.88 |
| Support Level | $27.84 | $132.50 |
| Resistance Level | $29.40 | $151.41 |
| Average True Range (ATR) | 0.51 | 6.74 |
| MACD | 0.01 | 1.51 |
| Stochastic Oscillator | 91.62 | 70.76 |
Price Performance
Historical ComparisonAbout KRG Kite Realty Group Trust
Kite Realty Group Trust specializing in high-quality, open-air shopping centers and mixed-use assets. Concentrated in the Sun Belt and strategic gateway markets, the company focuses on grocery-anchored, necessity-based retail. The company generates the majority of its revenue from contractual rents and reimbursement payments received from tenants.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.